News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Albireo (ALBO) Reports Second Quarter 2017 Financial Results



8/21/2017 8:17:01 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
BOSTON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today reported its financial results for the second quarter and six months ended June 30, 2017 and provided a business update.

“The Phase 3 clinical program for A4250, our promising IBAT inhibitor for the treatment of children with progressive familial intrahepatic cholestasis (PFIC), is planned to commence by the end of 2017. This program is an important step towards our goal of providing a new, non-surgical treatment for children afflicted with this life-altering disease,” said Ron Cooper, President and Chief Executive Officer of Albireo. “As we proceed with our Phase 3 plans for A4250, we were pleased to strengthen our balance sheet in the second quarter with the completion of an equity offering that resulted in approximately $48.5 million in new capital for Albireo.”

Read at GlobeNewswire


comments powered by Disqus
Albireo
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES